Skip to Main Content
Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of online calls, meetings, and deadlines has predictably returned. But you knew this was coming, yes? So time to fortify ourselves with a delicious cup of stimulation. Our choice today is the great pumpkin, so to speak. Feel free to join us. Meanwhile, we have taken advantage of some quiet time — courtesy of the snoozing official mascot — to assemble a few items of interest. Hope your day goes well and, as always, do keep in touch. We enjoy your postcards. …

Regeneron Pharmaceuticals (REGN) reported a single dose of its antibody cocktail reduced the risk of contracting Covid-19 by 81.6% in the two to eight months following administration in a late-stage trial, Reuters writes. The results showed the antibody therapy, REGEN-COV, may provide long-lasting immunity from Covid-19 infection, according to Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network. Such immunity is important for immunocompromised people and those not responding to vaccines. The therapy had previously shown an 81.4% reduction risk during the first month after administration.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment